Nicolás Meyer

15.5k total citations · 1 hit paper
189 papers, 4.7k citations indexed

About

Nicolás Meyer is a scholar working on Oncology, Molecular Biology and Epidemiology. According to data from OpenAlex, Nicolás Meyer has authored 189 papers receiving a total of 4.7k indexed citations (citations by other indexed papers that have themselves been cited), including 102 papers in Oncology, 51 papers in Molecular Biology and 47 papers in Epidemiology. Recurrent topics in Nicolás Meyer's work include Cancer Immunotherapy and Biomarkers (52 papers), Cutaneous Melanoma Detection and Management (37 papers) and CAR-T cell therapy research (31 papers). Nicolás Meyer is often cited by papers focused on Cancer Immunotherapy and Biomarkers (52 papers), Cutaneous Melanoma Detection and Management (37 papers) and CAR-T cell therapy research (31 papers). Nicolás Meyer collaborates with scholars based in France, United States and Australia. Nicolás Meyer's co-authors include C. Paul, Laurence Lamant, Bruno Ségui, Nathalie Andrieu‐Abadie, Thierry Levade, Céline Colacios, Anne Montfort, Laurent Mortier, Jean‐Jacques Grob and V. Sibaud and has published in prestigious journals such as Nature Communications, Journal of Clinical Oncology and SHILAP Revista de lepidopterología.

In The Last Decade

Nicolás Meyer

172 papers receiving 4.6k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Dabrafenib plus trametinib in patients with BRAFV600-mutant melanoma brain metastases (COMBI-MB): a multicentre, multicohort, open-label, phase 2 trial

2017 482 citations Philippe Saïag, Caroline Robert et al. The Lancet Oncology profile →

Peers

Countries citing papers authored by Nicolás Meyer

Since Specialization

Citations

This map shows the geographic impact of Nicolás Meyer's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Nicolás Meyer with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Nicolás Meyer more than expected).

Fields of papers citing papers by Nicolás Meyer

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Nicolás Meyer. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Nicolás Meyer. The network helps show where Nicolás Meyer may publish in the future.

Co-authorship network of co-authors of Nicolás Meyer

This figure shows the co-authorship network connecting the top 25 collaborators of Nicolás Meyer. A scholar is included among the top collaborators of Nicolás Meyer based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Nicolás Meyer. Nicolás Meyer is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Triplet combination treatments with pembrolizumab (pembro) for anti–PD-(L)1–refractory advanced melanoma: Preliminary results of the phase 1/2 KEYMAKER-U02A study. 2024 ·Journal of Clinical Oncology ·Reinhard Dummer, Jean‐Jacques Grob, Caroline Robert, Ronnie Shapira‐Frommer, Célèste Lebbé, Paolo A. Ascierto, Stéphane Dalle, Omid Hamid, Nicolás Meyer, Muhammad Adnan Khattak, Andrew Hill, Jonathan Cohen, Giuseppe Curigliano, Anna Maria Di Giacomo, Michele Del Vecchio, Sekwon Jang, (unknown), Xuan Peng, Scott J. Diede, Georgina V. Long	2
2	Pembrolizumab for Locally Advanced or Recurrent/Metastatic Cutaneous Squamous Cell Carcinoma: Long-Term Results of the Phase 2 Keynote-629 Study 2024 ·(unknown), (unknown), Laurent Mortier, Jean‐Jacques Grob, Ralf Gutzmer, Osama Roshdy, (unknown), Jacob Schachter, Ana Arance, (unknown), Nicolás Meyer, Abhishek Joshi, Salem Billan, (unknown), Jianda Yuan, (unknown), Å. Bratland	0
3	Tyrosine kinase inhibitors in cancers: Treatment optimization – Part I 2024 ·Critical Reviews in Oncology/Hematology ·(unknown), L. Dousset, Stéphane Bouchet, (unknown), (unknown), Célèste Lebbé, Joseph Ciccolini, Nicolás Meyer, Angélo Paci	3
4	1140P Cemiplimab versus historical systemic treatments for locally advanced (la) or metastatic (m) cutaneous squamous cell carcinomas (CSCC): Results from the French study TOSCA 2023 ·Annals of Oncology ·E. Gérard, Célèste Lebbé, Émilie Lanoy, G. Quéreux, Philippe Bernard, (unknown), Nicolás Meyer, Laurent Mortier, (unknown), Délphine Legoupil, Eve‐Marie Neidhardt, Philippe Saïag, (unknown), P. Celérier, Charlée Nardin, E. Maubec, (unknown), Stéphanie Perrier, (unknown), Caroline Robert	3
5	Understanding the Lived Experiences of Patients With Melanoma: Real-World Evidence Generated Through a European Social Media Listening Analysis 2022 ·JMIR Cancer ·(unknown), (unknown), Iván Márquez‐Rodas, Luigi Formisano, Sophie Papa, Nicolás Meyer, Andrea Forschner, Guy Faust, Mike Lau, Alexandros Sagkriotis	5
6	Radial neck osteolysis after radial head replacement: Functional impact and risk factors 2022 ·Orthopaedics & Traumatology Surgery & Research ·(unknown), (unknown), Nicolás Meyer, Philippe Clavert	3
7	Efficacy of sonic hedgehog inhibitors rechallenge, after initial complete response in recurrent advanced basal cell carcinoma: a retrospective study from the CARADERM database 2021 ·ESMO Open ·(unknown), S. Dalac, Brigitte Dréno, Eve‐Marie Neidhardt, E. Maubec, (unknown), Fabrice André, Hélène Behal, (unknown), Guido Bens, M.‐T. Leccia, Nicolás Meyer, F. Granel‐Brocard, M. Beylot‐Barry, O. Dereure, Nicole Basset‐Séguin, Laurent Mortier	14
8	Prognostic factors for traumatic elbow osteoarthritis after terrible triad surgery, and functional impact 2021 ·Orthopaedics & Traumatology Surgery & Research ·(unknown), (unknown), (unknown), Nicolás Meyer, Philippe Clavert	5
9	Renal Complications Related to Checkpoint Inhibitors: Diagnostic and Therapeutic Strategies 2021 ·Diagnostics ·Julie Bellière, Julien Mazières, Nicolás Meyer, Leila Chebane, Fabien Despas	11
10	Combining Nivolumab and Ipilimumab with Infliximab or Certolizumab in Patients with Advanced Melanoma: First Results of a Phase Ib Clinical Trial 2020 ·Clinical Cancer Research ·Anne Montfort, Thomas Filleron, (unknown), (unknown), (unknown), Cécile Pagès, Pascale Olivier, Maha Ayyoub, (unknown), Amélie Lusque, Stéphanie Brayer, Jean‐Pierre Delord, Nathalie Andrieu‐Abadie, Thierry Levade, Céline Colacios, Bruno Ségui, Nicolás Meyer	70
11	Management of adjuvant settings for Stage III melanoma patients in France prior to checkpoint inhibitors: epidemiological data from the RIC-Mel database 2020 ·European Journal of Dermatology ·Stéphane Dalle, Émilie Varey, Jean‐Michel Nguyen, A. Dupuy, Henri Montaudié, C. Lesage, Laurent Mortier, M.‐T. Leccia, F. Skowron, P. Celérier, Nicolás Meyer, Caroline Dutriaux, (unknown), Amir Khammari, Célèste Lebbé, Brigitte Dréno	1
12	Targeting the Sphingosine 1-Phosphate Axis Exerts Potent Antitumor Activity in BRAFi-Resistant Melanomas 2018 ·Molecular Cancer Therapeutics ·David Garandeau, (unknown), J. C. Leclerc, Caroline Imbert, Virginie Garcia, Marie‐Lise Bats, Florian Rambow, Julia Gilhodes, Thomas Filleron, Nicolás Meyer, Stéphanie Brayer, (unknown), Sophie Tartare‐Deckert, Bruno Ségui, Jean‐Christophe Marine, Thierry Levade, Corine Bertolotto, Nathalie Andrieu‐Abadie	26
13	Compounded topical preparations in plaque psoriasis: Still a place for it in 2018? 2018 ·Dermatologic Therapy ·(unknown), (unknown), M. Tauber, (unknown), C. Bulaï Livideanu, J. Mazereeuw‐Hautier, Nicolás Meyer, C. Paul	0
14	Early Circulating Tumour DNA Variations Predict Tumour Response in Melanoma Patients Treated with Immunotherapy 2018 ·Acta Dermato Venereologica ·Laura Keller, Nicolas Guibert, Alfredo G. Casanova, Stéphanie Brayer, Mauro Farella, M. Delaunay, Julia Gilhodes, E. Martin, G Balagué, Gilles Favre, Anne Pradines, Nicolás Meyer	23
15	Les agglomérations de Sarrebourg/Pons Saravi (Moselle) et de Saverne/Tabernis-Tres Tabernae (Bas-Rhin) : deux destins de part et d’autre des Vosges durant l’Antiquité tardive 2017 ·Gallia ·Nicolás Meyer	0
16	Vismodegib in patients with advanced basal cell carcinoma (STEVIE): a pre-planned interim analysis of an international, open-label trial 2015 ·The Lancet Oncology ·Nicole Basset‐Séguin, Axel Hauschild, Jean‐Jacques Grob, Rainer Kunstfeld, Brigitte Dréno, Laurent Mortier, (unknown), Lisa Licitra, Caroline Dutriaux, L. Thomas, Thomas Jouary, Nicolás Meyer, B. Guillot, Reinhard Dummer, Kate Fife, D. Scott Ernst, Sarah Williams, A. Fittipaldo, Ioannis Xynos, Johan Hansson	170
17	CD10 expression by melanoma cells is associated with aggressive behavior in vitro and predicts rapid metastatic progression in humans 2012 ·Journal of Dermatological Science ·(unknown), Jean‐Philippe Annereau, (unknown), Nicolas Guilbaud, I. Garrido, C. Paul, Pierre Brousset, Laurence Lamant, Nicolás Meyer	17
18	Chromosomal Instability in Near-Diploid Colorectal Cancer: A Link between Numbers and Structure 2008 ·PLoS ONE ·Martine Muleris, Alexandra Chalastanis, Nicolás Meyer, Marick Laé, Bernard Dutrillaux, Xavier Sastre‐Garau, Richard Hamelin, Jean–François Fléjou, Alex Duval	15
19	Identification of a Novel CD160+CD4+ T-Lymphocyte Subset in the Skin: A Possible Role for CD160 in Skin Inflammation 2007 ·Journal of Investigative Dermatology ·(unknown), Jérôme Giustiniani, Nicolás Meyer, Valérie Schiavon, Nicolás Ortonne, José A. Campillo, Martine Bagot, Armand Bensussan	27
20	Awareness, knowledge and attitudes towards sun protection among skin cancer‐treated patients in France 2007 ·Journal of the European Academy of Dermatology and Venereology ·Nicolás Meyer, (unknown), E. Bourdon‐Lanoy, E. Maubec, (unknown)	25

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact